Understand the source comparison
ARA-290 Innate Repair Receptor Activation: Research Comparison
Understanding how ARA-290 compares to related compounds clarifies its distinct advantages for studying innate repair mechanisms versus hematopoietic or broadly immunosuppressive pathways. ARA-290 Selective IRR (CD131/EPOR heterodimer) agonist Yes—no effect on
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- Understanding how ARA-290 compares to related compounds clarifies its distinct advantages for studying innate repair mechanisms versus hematopoietic or broadly immunosuppressive pathways.
- ARA-290
- Selective IRR (CD131/EPOR heterodimer) agonist
- Yes—no effect on hematocrit across clinical trials
- TNF-α reduced 40–55%, IL-6 reduced 35–50% via NF-κB inhibition
- Phase II completed in neuropathic pain, corneal injury, type 2 diabetes
- Isolates tissue-protective EPO effects without thrombotic risk—ideal for chronic inflammation research
- Erythropoietin (EPO)
- Dual agonist: EPOR homodimer (hematopoiesis) and EPOR/CD131 heterodimer (tissue protection)
- No—increases hematocrit 6–12% at tissue-protective doses, elevating thrombotic risk
- Similar cytokine effects to ARA-290 but confounded by polycythemia and cardiovascular changes
- Extensive cardiovascular and renal trial data; tissue protection is secondary effect
- Provides tissue protection but hematologic effects limit long-term use in non-anemic conditions
- Dexamethasone
- Glucocorticoid receptor agonist causing broad immunosuppression
- No—suppresses inflammation but does not activate repair signaling
- Reduces all inflammatory cytokines through transcriptional repression
- Gold standard anti-inflammatory across dozens of indications
- Suppresses symptoms but delays healing; opposite mechanism to innate repair activation
- Thymosin Alpha-1
- Toll-like receptor and T-cell modulator enhancing adaptive immunity
- Partial—improves wound healing but through immune activation rather than direct tissue protection
- Increases IL-2 and IFN-γ (pro-immune); reduces IL-6 modestly in sepsis models
- Phase III data in hepatitis, sepsis, immune deficiency
- Immune potentiation strategy rather than repair receptor engagement—different research application
- BPC-157
- Mechanism incompletely characterized; proposed VEGF pathway and nitric oxide modulation
- Yes—demonstrates tissue healing without hematopoietic changes
- Anti-inflammatory effects reported but cytokine pathways not well defined in peer-reviewed literature
- Limited human data; primarily animal model evidence
- Promising tissue repair profile but mechanistic uncertainty limits comparative research utility
- ARA-290's selectivity for the innate repair receptor over the erythropoietic receptor represents the critical differentiator. This allows researchers to isolate tissue-protective and anti-inflammatory signaling from the confounding cardiovascular and thrombotic effects that complicate EPO research. For institutions studying chronic neuropathy, inflammatory bowel disease, or ischemic injuries where months-long intervention is required, ARA-290 provides a safety profile that full-length EPO cannot match.